Philips Launches AI-Powered SmartSpeed Precise MRI Software at ECR
The updated software reportedly enables a threefold improvement in MRI scan time and enhanced image sharpness.
Philips has unveiled SmartSpeed Precise, an artificial intelligence (AI) software that may significantly bolster scan times and image sharpness with MRI scans.
Launched at the European Congress of Radiology (ECR) conference, the SmartSpeed Precise software allows up to a threefold reduction in MRI scan times, according to Philips.
Here one can see a pelvic MRI with use of the SmartSpeed Precise technology on a Philips Ingenia Evolution MR 3T scanner. The SmartSpeed Precise software, which is being launched at the European Congress of Radiology (ECR) conference, reportedly facilitates an 80 percent improvement in image sharpness on MRI. (Image courtesy of Philips.)
Incorporating the company’s Compressed SENSE and SmartSpeed technologies, Philips said the next-generation SmartSpeed Precise software facilitates detection of subtle abnormalities with an 80 percent improvement in image sharpness.
“We are impressed by the extremely sharp and crisp images, diagnostic confidence, and fast scans delivered by the dual-AI SmartSpeed Precise solution. We expect it will set a new standard in clinical performance with its ease of use, high image quality, and acceleration controlled by a single parameter,” noted Wayne Picker, a vice president of clinical technology at Prenuvo, Inc.
Meta-Analysis Shows Merits of AI with CTA Detection of Coronary Artery Stenosis and Calcified Plaque
April 16th 2025Artificial intelligence demonstrated higher AUC, sensitivity, and specificity than radiologists for detecting coronary artery stenosis > 50 percent on computed tomography angiography (CTA), according to a new 17-study meta-analysis.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
